Optimizing HER2-Targeted Therapy in NSCLC: Role of Pharmacists and Community Adoption

This episode discusses the critical role of pharmacists in optimizing HER2-targeted therapy for non-small cell lung cancer (NSCLC), especially as these therapies are adopted more widely in community settings. Pharmacists are recognized for their expertise in reviewing prescriptions for proper dosing and potential drug interactions, proactively educating patients about expected side effects, and monitoring patients' tolerance to treatment over time. Their involvement includes offering follow-up support, addressing patient questions, and coordinating with oncologists to ensure safe and effective therapy use. The discussion acknowledges variability in pharmacist resources between academic centers and community oncology practices, emphasizing that not all community sites may have access to dedicated oncology pharmacists. Additionally, the shift toward more oral HER2-targeted therapies is highlighted as a facilitator for broader adoption in community settings, as these agents generally require less frequent in-person monitoring and can expand treatment access for patients in rural or remote areas.